vs
PROGRESS SOFTWARE CORP（PRGS）とTransMedics Group, Inc.（TMDX）の財務データ比較。上の社名をクリックして会社を切り替えられます
PROGRESS SOFTWARE CORPの直近四半期売上が大きい（$252.7M vs $160.8M、TransMedics Group, Inc.の約1.6倍）。TransMedics Group, Inc.の純利益率が高く（65.6% vs 10.2%、差は55.4%）。TransMedics Group, Inc.の前年同期比売上増加率が高い（32.2% vs 17.5%）。PROGRESS SOFTWARE CORPの直近四半期フリーキャッシュフローが多い（$59.9M vs $19.0M）。過去8四半期でTransMedics Group, Inc.の売上複合成長率が高い（28.8% vs 17.0%）
プログレスソフトウェアコーポレーションは、アプリケーション開発プラットフォーム、データ接続ツール、デジタルエクスペリエンスソリューションなどの企業向けソフトウェアを開発・販売しています。金融、医療、製造、小売など世界中の多様な業界の顧客にサービスを提供し、業務効率化と高性能業務アプリの構築を支援しています。
TransMedics Group, Inc.は臓器移植向けの革新的な医療技術を開発・販売する企業です。主力製品の臓器ケアシステムは輸送中のドナー臓器の生存性を維持し、心臓、肺、肝臓、腎臓移植の成功率向上に貢献し、北米、欧州、アジア太平洋地域の移植センターなどにサービスを提供しています。
PRGS vs TMDX — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $252.7M | $160.8M |
| 純利益 | $25.7M | $105.4M |
| 粗利率 | 81.6% | 58.1% |
| 営業利益率 | 15.2% | 13.2% |
| 純利益率 | 10.2% | 65.6% |
| 売上前年比 | 17.5% | 32.2% |
| 純利益前年比 | 2144.6% | 1436.9% |
| EPS（希薄化後） | $0.59 | $2.59 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $252.7M | $160.8M | ||
| Q3 25 | $249.8M | $143.8M | ||
| Q2 25 | $237.4M | $157.4M | ||
| Q1 25 | $238.0M | $143.5M | ||
| Q4 24 | $215.0M | $121.6M | ||
| Q3 24 | $178.7M | $108.8M | ||
| Q2 24 | $175.1M | $114.3M | ||
| Q1 24 | $184.7M | $96.8M |
| Q4 25 | $25.7M | $105.4M | ||
| Q3 25 | $19.4M | $24.3M | ||
| Q2 25 | $17.0M | $34.9M | ||
| Q1 25 | $10.9M | $25.7M | ||
| Q4 24 | $1.1M | $6.9M | ||
| Q3 24 | $28.5M | $4.2M | ||
| Q2 24 | $16.2M | $12.2M | ||
| Q1 24 | $22.6M | $12.2M |
| Q4 25 | 81.6% | 58.1% | ||
| Q3 25 | 81.0% | 58.8% | ||
| Q2 25 | 80.1% | 61.4% | ||
| Q1 25 | 80.6% | 61.5% | ||
| Q4 24 | 83.0% | 59.2% | ||
| Q3 24 | 83.7% | 55.9% | ||
| Q2 24 | 81.7% | 60.6% | ||
| Q1 24 | 82.2% | 61.9% |
| Q4 25 | 15.2% | 13.2% | ||
| Q3 25 | 17.6% | 16.2% | ||
| Q2 25 | 16.3% | 23.2% | ||
| Q1 25 | 13.6% | 19.1% | ||
| Q4 24 | 10.0% | 7.1% | ||
| Q3 24 | 22.6% | 3.6% | ||
| Q2 24 | 15.5% | 10.9% | ||
| Q1 24 | 19.0% | 12.8% |
| Q4 25 | 10.2% | 65.6% | ||
| Q3 25 | 7.8% | 16.9% | ||
| Q2 25 | 7.2% | 22.2% | ||
| Q1 25 | 4.6% | 17.9% | ||
| Q4 24 | 0.5% | 5.6% | ||
| Q3 24 | 15.9% | 3.9% | ||
| Q2 24 | 9.2% | 10.7% | ||
| Q1 24 | 12.3% | 12.6% |
| Q4 25 | $0.59 | $2.59 | ||
| Q3 25 | $0.44 | $0.66 | ||
| Q2 25 | $0.39 | $0.92 | ||
| Q1 25 | $0.24 | $0.70 | ||
| Q4 24 | $0.01 | $0.19 | ||
| Q3 24 | $0.65 | $0.12 | ||
| Q2 24 | $0.37 | $0.35 | ||
| Q1 24 | $0.51 | $0.35 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $94.8M | — |
| 総負債低いほど良い | $1.4B | — |
| 株主資本純資産 | $478.3M | $473.1M |
| 総資産 | $2.5B | $1.1B |
| 負債/資本比率低いほどレバレッジが低い | 2.93× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $94.8M | — | ||
| Q3 25 | $99.0M | — | ||
| Q2 25 | $102.0M | — | ||
| Q1 25 | $124.2M | — | ||
| Q4 24 | $118.1M | — | ||
| Q3 24 | $232.7M | $330.1M | ||
| Q2 24 | $190.4M | $362.8M | ||
| Q1 24 | $133.2M | $350.2M |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $478.3M | $473.1M | ||
| Q3 25 | $477.7M | $355.2M | ||
| Q2 25 | $452.7M | $318.1M | ||
| Q1 25 | $431.8M | $266.3M | ||
| Q4 24 | $438.8M | $228.6M | ||
| Q3 24 | $425.6M | $209.9M | ||
| Q2 24 | $401.7M | $189.9M | ||
| Q1 24 | $461.7M | $159.5M |
| Q4 25 | $2.5B | $1.1B | ||
| Q3 25 | $2.4B | $946.0M | ||
| Q2 25 | $2.4B | $890.5M | ||
| Q1 25 | $2.5B | $837.5M | ||
| Q4 24 | $2.5B | $804.1M | ||
| Q3 24 | $1.6B | $785.6M | ||
| Q2 24 | $1.6B | $758.6M | ||
| Q1 24 | $1.5B | $723.8M |
| Q4 25 | 2.93× | — | ||
| Q3 25 | 2.97× | — | ||
| Q2 25 | 3.22× | — | ||
| Q1 25 | 3.50× | — | ||
| Q4 24 | 3.48× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $62.8M | $34.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $59.9M | $19.0M |
| FCFマージンFCF / 売上 | 23.7% | 11.8% |
| 設備投資強度設備投資 / 売上 | 1.1% | 9.7% |
| キャッシュ転換率営業CF / 純利益 | 2.44× | 0.33× |
| 直近12ヶ月FCF直近4四半期 | $229.5M | $133.6M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $62.8M | $34.5M | ||
| Q3 25 | $73.4M | $69.6M | ||
| Q2 25 | $30.0M | $91.6M | ||
| Q1 25 | $68.9M | $-2.9M | ||
| Q4 24 | $19.7M | $19.7M | ||
| Q3 24 | $57.7M | $6.9M | ||
| Q2 24 | $63.7M | $25.7M | ||
| Q1 24 | $70.5M | $-3.4M |
| Q4 25 | $59.9M | $19.0M | ||
| Q3 25 | $72.4M | $61.9M | ||
| Q2 25 | $29.5M | $82.5M | ||
| Q1 25 | $67.7M | $-29.9M | ||
| Q4 24 | $16.8M | $6.1M | ||
| Q3 24 | $56.6M | $-41.3M | ||
| Q2 24 | $62.7M | $2.0M | ||
| Q1 24 | $70.2M | $-47.6M |
| Q4 25 | 23.7% | 11.8% | ||
| Q3 25 | 29.0% | 43.1% | ||
| Q2 25 | 12.4% | 52.4% | ||
| Q1 25 | 28.4% | -20.8% | ||
| Q4 24 | 7.8% | 5.0% | ||
| Q3 24 | 31.7% | -38.0% | ||
| Q2 24 | 35.8% | 1.7% | ||
| Q1 24 | 38.0% | -49.2% |
| Q4 25 | 1.1% | 9.7% | ||
| Q3 25 | 0.4% | 5.3% | ||
| Q2 25 | 0.2% | 5.8% | ||
| Q1 25 | 0.5% | 18.8% | ||
| Q4 24 | 1.3% | 11.2% | ||
| Q3 24 | 0.6% | 44.3% | ||
| Q2 24 | 0.5% | 20.8% | ||
| Q1 24 | 0.2% | 45.6% |
| Q4 25 | 2.44× | 0.33× | ||
| Q3 25 | 3.78× | 2.86× | ||
| Q2 25 | 1.76× | 2.62× | ||
| Q1 25 | 6.30× | -0.11× | ||
| Q4 24 | 17.13× | 2.87× | ||
| Q3 24 | 2.03× | 1.63× | ||
| Q2 24 | 3.93× | 2.11× | ||
| Q1 24 | 3.11× | -0.28× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PRGS
| Maintenanceand Services | $187.5M | 74% |
| Share File Acquisition | $67.5M | 27% |
TMDX
| Liver Product | $127.0M | 79% |
| Heart Product | $26.0M | 16% |
| Other | $5.9M | 4% |
| Lung Product | $1.9M | 1% |
